Verastem (VSTM) Cost of Revenue (2018 - 2026)

Verastem (VSTM) recorded quarterly Cost of Revenue of $2.8 million in Q1 2026, up 6.13% quarter-over-quarter from $2.6 million in Q4 2025.

Verastem (VSTM) Cost of Revenue (2018 - 2026) Analysis & Trends

Verastem's Cost of Revenue history runs 5 years deep, the most recent figure standing at $2.8 million for Q1 2026.

In Q1 2026, Cost of Revenue changed N/A year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $7.4 million (changed N/A YoY), while the FY2025 annual figure was $4.6 million, changed N/A from the prior year.
Cost of Revenue was $2.8 million for Q1 2026 at Verastem, up from $2.6 million in the prior quarter.
In the past five years, Cost of Revenue ranged from a high of $2.8 million in Q1 2026 to a low of $318000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	64.20 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	48,670.00
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	392.80 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	2.05 Mn
10	Verastem	407.42 Mn	225.74 Mn	15.90 Mn	2.77 Mn

Download Data